VA's $1.4B Pharmaceutical Prime Vendor Contract Awarded to McKesson Corporation for FY2026
Contract Overview
Contract Amount: $1,406,868,182 ($1.4B)
Contractor: Mckesson Corporation
Awarding Agency: Department of Veterans Affairs
Start Date: 2025-11-01
End Date: 2025-11-30
Sector: Healthcare
Official Description: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
Plain-Language Summary
Department of Veterans Affairs obligated $1.41 billion to MCKESSON CORPORATION for work described as: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER Key points: 1. The Department of Veterans Affairs (VA) awarded a significant contract valued at over $1.4 billion. 2. McKesson Corporation, a major player in pharmaceutical distribution, secured this prime vendor contract. 3. The contract covers pharmaceutical supplies for the fiscal year 2026, indicating ongoing demand. 4. This award highlights the critical role of large distributors in government healthcare procurement.
Value Assessment
Rating: good
The contract value of $1.4 billion for a single fiscal year suggests a substantial volume of pharmaceutical purchases. Benchmarking against similar large-scale pharmaceutical distribution contracts would be necessary for a precise pricing assessment, but the scale implies competitive pricing is likely sought.
Cost Per Unit: N/A
Competition Analysis
Competition Level: unknown
The contract type is a Delivery Order, suggesting it may be part of a larger indefinite-delivery/indefinite-quantity (IDIQ) contract or a competitive process. The specific competition method is not detailed, but large contracts like this often involve significant price discovery through bidding.
Taxpayer Impact: The efficient procurement of pharmaceuticals through a prime vendor model aims to control costs and ensure timely access to medications for veterans, ultimately benefiting taxpayers by streamlining the supply chain.
Public Impact
Ensures access to a wide range of pharmaceuticals for veterans. Supports the VA's mission to provide comprehensive healthcare services. Potential for cost savings through bulk purchasing and efficient distribution. Reliability of supply chain for critical medications.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Lack of detailed competition information.
- Potential for price fluctuations in pharmaceutical markets.
- Dependence on a single vendor for critical supplies.
Positive Signals
- Significant contract value indicates strong demand and potential for economies of scale.
- Award to a known, large distributor suggests established supply chain capabilities.
- Focus on a specific fiscal year allows for targeted budget allocation.
Sector Analysis
The healthcare sector, particularly pharmaceutical procurement, is a massive area of government spending. Large prime vendor contracts like this are common for ensuring the efficient and cost-effective distribution of medications to government agencies and beneficiaries.
Small Business Impact
This contract appears to be awarded to a large corporation, McKesson. There is no immediate indication of specific provisions or set-asides for small businesses within this particular award notice. Further analysis of the parent contract or related solicitations would be needed to assess small business participation.
Oversight & Accountability
The Department of Veterans Affairs is responsible for overseeing this contract. Standard oversight mechanisms would include performance monitoring, quality assurance, and financial audits to ensure compliance with contract terms and efficient use of taxpayer funds.
Related Government Programs
- Department of Veterans Affairs Contracting
- Department of Veterans Affairs Programs
Risk Flags
- Potential for price increases due to market volatility.
- Risk of supply chain disruptions (e.g., manufacturing issues, natural disasters).
- Over-reliance on a single large vendor.
- Ensuring equitable access to all necessary medications.
- Cybersecurity risks associated with handling sensitive pharmaceutical data.
Tags
department-of-veterans-affairs, delivery-order, billion-dollar
Frequently Asked Questions
What is this federal contract paying for?
Department of Veterans Affairs awarded $1.41 billion to MCKESSON CORPORATION. EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
Who is the contractor on this award?
The obligated recipient is MCKESSON CORPORATION.
Which agency awarded this contract?
Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).
What is the total obligated amount?
The obligated amount is $1.41 billion.
What is the period of performance?
Start: 2025-11-01. End: 2025-11-30.
What is the historical pricing trend for pharmaceutical prime vendor contracts of similar scope awarded by the VA or other federal agencies?
Analyzing historical pricing data for comparable pharmaceutical prime vendor contracts is crucial for assessing value. Factors such as drug inflation, volume discounts, and contract terms significantly influence pricing. Benchmarking against previous VA contracts or similar large-scale federal awards can reveal whether McKesson's pricing is competitive or if there are opportunities for cost savings through renegotiation or alternative procurement strategies.
What are the specific performance metrics and service level agreements (SLAs) included in this contract to mitigate supply chain risks?
The contract likely includes specific performance metrics and SLAs related to delivery timeliness, order accuracy, inventory management, and product quality. Robust SLAs are essential for mitigating risks associated with pharmaceutical supply chains, such as stockouts, expired medications, or delivery delays. Understanding these terms will clarify the VA's strategy for ensuring reliable access to critical medicines for veterans.
How does the VA ensure the effectiveness of the Pharmaceutical Prime Vendor program in meeting the diverse pharmaceutical needs of its patient population?
The VA ensures program effectiveness through continuous monitoring of drug utilization patterns, patient feedback, and clinical outcomes. The prime vendor model is designed to provide a broad formulary and efficient distribution, but the VA likely supplements this with internal formulary management and direct purchasing for specialized or high-cost drugs. Regular performance reviews with McKesson are key to adapting to evolving healthcare needs.
More Contracts from Mckesson Corporation
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2026 October — $1.2B (Department of Veterans Affairs)
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2025 September — $1.2B (Department of Veterans Affairs)
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2025 July — $1.1B (Department of Veterans Affairs)
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2026 December — $1.1B (Department of Veterans Affairs)
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2026 January — $1.1B (Department of Veterans Affairs)
Other Department of Veterans Affairs Contracts
- CCN Region 3 Express Report — $5.2B (Optum Public Sector Solutions, Inc.)
- Express Report for FY22 Region 2 — $5.1B (Optum Public Sector Solutions, Inc.)
- Fiscal Year 2022 Express Report for Region 1 — $4.2B (Optum Public Sector Solutions, Inc.)
- Express Report for the Patient Centered Community Care (PC3) Contract — $3.3B (Triwest Healthcare Alliance Corp)
- CCN Region Three FY21 Express Report — $3.1B (Optum Public Sector Solutions, Inc.)